Results 201 to 210 of about 25,852 (233)
Some of the next articles are maybe not open access.
Switching P2Y12 Receptor Inhibiting Therapies
Interventional Cardiology Clinics, 2017Antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor is the cornerstone of treatment of patients with atherothrombotic disease manifestations. Switching between P2Y12 inhibitors occurs commonly in clinical practice for a variety of reasons, including safety, efficacy, adherence, and economic considerations.
Fabiana, Rollini +2 more
openaire +2 more sources
Pharmacology: Inhibitors of P2Y12
2017Dual antiplatelet treatment consisting of aspirin and a P2Y12 inhibitor represents the cornerstone of treatment in patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary intervention. P2Y12 inhibitors are broadly used worldwide to prevent and treat ischemic events in cardiac patients; however, understanding their ...
Lisa Gross, Dániel Aradi, Dirk Sibbing
openaire +1 more source
Clinical Hemorheology and Microcirculation, 2021
BACKGROUND: Analyzing responsiveness to P2Y12 therapy is vital to preventing thrombotic and hemorrhagic complications in patients with cardiovascular diseases. OBJECTIVE: This study evaluates a new Anysis-P2Y12 assay system against ...
Jinxiang, Piao +5 more
openaire +2 more sources
BACKGROUND: Analyzing responsiveness to P2Y12 therapy is vital to preventing thrombotic and hemorrhagic complications in patients with cardiovascular diseases. OBJECTIVE: This study evaluates a new Anysis-P2Y12 assay system against ...
Jinxiang, Piao +5 more
openaire +2 more sources
Heart, 2011
The management and prevention of arterial thrombosis has been transformed by the recognition of the role of platelets in this process and the development of effective antiplatelet drugs. The limited role of thromboxane A2 in platelet activation explains why aspirin therapy, which effectively inhibits release of thromboxane A2 by platelets, is ...
openaire +1 more source
The management and prevention of arterial thrombosis has been transformed by the recognition of the role of platelets in this process and the development of effective antiplatelet drugs. The limited role of thromboxane A2 in platelet activation explains why aspirin therapy, which effectively inhibits release of thromboxane A2 by platelets, is ...
openaire +1 more source
Thrombosis and Haemostasis, 2013
SummaryVerifyNow (VN) P2Y12 is a point-of-care assay used to assess response to P2Y12 inhibitors. Sodium citrate (citrate) is the standard anticoagulant used for this assay but requires a pre-incubation period. Hirudin is an alternative anticoagulant for platelet function studies that maintains physiological divalent cation levels.
Robert Storey +8 more
openaire +1 more source
SummaryVerifyNow (VN) P2Y12 is a point-of-care assay used to assess response to P2Y12 inhibitors. Sodium citrate (citrate) is the standard anticoagulant used for this assay but requires a pre-incubation period. Hirudin is an alternative anticoagulant for platelet function studies that maintains physiological divalent cation levels.
Robert Storey +8 more
openaire +1 more source
P2Y12 Is Involved in Cancer Metastasis,
Blood, 2011Abstract Abstract 3356 The platelet ADP receptor P2Y12 plays a prominent role in amplifying platelet activation, aggregation and thrombus formation, and the P2Y12 inhibitor Clopidogrel is widely used clinically to treat coronary artery, peripheral vascular and cerebrovascular diseases.
Yanhua Wang +8 more
openaire +1 more source
Blood, 2006
Abstract Affinity of platelet integrin αIIbβ3 for ligands is dynamically regulated and the activation of αIIbβ3 has been analyzed by binding assays using fibrinogen or ligand mimetic antibodies such as PAC1. Ligand binding assays are suitable for the condition when the number of receptors would reach a plateau phase before the end of ...
Masamichi Shiraga +8 more
openaire +1 more source
Abstract Affinity of platelet integrin αIIbβ3 for ligands is dynamically regulated and the activation of αIIbβ3 has been analyzed by binding assays using fibrinogen or ligand mimetic antibodies such as PAC1. Ligand binding assays are suitable for the condition when the number of receptors would reach a plateau phase before the end of ...
Masamichi Shiraga +8 more
openaire +1 more source
Biology and Pharmacology of the Platelet P2Y12 Receptor
Current Pharmaceutical Design, 2006Platelets possess two receptors for ADP, P2Y(1) and P2Y(12). ADP is released from platelet dense granules upon platelet activation by numerous agonists and thereby amplifies platelet responses regardless of the initial stimulus. The P2Y(1) receptor is one of many platelet receptors coupled to Gq and initiates ADP-induced activation.
openaire +2 more sources
Arteriosclerosis, Thrombosis, and Vascular Biology, 2015
Introduction: Little is known about the role of P2Y12 oligomerization in receptor function and whether P2Y12 receptor mutations associated with human bleeding disorders may be explained by alterations in oligomerization. Objectives: 1) To determine whether P2Y12 homo- and ...
Aasma Khan +2 more
openaire +1 more source
Introduction: Little is known about the role of P2Y12 oligomerization in receptor function and whether P2Y12 receptor mutations associated with human bleeding disorders may be explained by alterations in oligomerization. Objectives: 1) To determine whether P2Y12 homo- and ...
Aasma Khan +2 more
openaire +1 more source
Thienopyrimidine-based P2Y12 platelet aggregation inhibitors
Bioorganic & Medicinal Chemistry Letters, 2009Herein we describe the design and synthesis of a novel series of potent thienopyrimidine P2Y12 inhibitors and the negative impact protein binding has on the inhibition of platelet aggregation.
Steven W, Kortum +7 more
openaire +2 more sources